Investing Pioneers
SUBSCRIBE NOW
  • Wall Street Word
  • Whale Tracker
  • Stocks
  • Gold
  • Crypto
  • Economy
No Result
View All Result
  • Wall Street Word
  • Whale Tracker
  • Stocks
  • Gold
  • Crypto
  • Economy
No Result
View All Result
Investing Pioneers
No Result
View All Result

Elon Musk’s Drug Choice Sparks Investor Curiosity

in Wall Street Word
0
0
SHARES
370
VIEWS
Share on FacebookShare on Twitter

The world’s richest man Elon Musk earlier this week admitted to using the weight loss drug Mounjaro.

What Happened: Musk on Christmas posted a picture of himself donning the Santa Claus costume with the caption “Ozempic Santa.”

Ozempic Santa pic.twitter.com/7YECSNpWoz

— Elon Musk (@elonmusk) December 26, 2024

The billionaire later clarified that he uses Mounjaro but chose to caption his picture otherwise as Mounjaro doesn’t have the same “ring” to it as Ozempic.

Musk said that he chose Mounjaro produced by Eli Lilly (NYSE:LLY) over Ozempic produced by Novo Nordisk A/S (NYSE:NVO) owing to seemingly fewer side effects.

“High doses of Ozempic made me fart & burp like Barney from the Simpson’s. Mounjaro seems to have fewer side effects and be more effective,” he said.

High doses of Ozempic made me fart & burp like Barney from the Simpson’s 🤣

Mounjaro seems to have fewer side effects and be more effective.

— Elon Musk (@elonmusk) December 26, 2024

Musk has previously voiced his support for weight loss drugs saying that the health benefits of reducing obesity far exceed the side effects of using the drugs.

“While no drug is without side effects, health problems associated with obesity almost certainly exceed the risks of GLP-1 agonists,” Musk said as early as Oct. 2023. GLP-1 agonists are a class of medications that can help manage Type 2 diabetes and obesity.

Why It Matters: While Musk, who was named by President-elect Donald Trump to lead the Department of Government Efficiency, is all for weight-loss drugs, Robert F. Kennedy Jr. is not.

In November, Trump selected Kennedy Jr., known for his outspoken skepticism about vaccines, to lead the Department of Health and Human Services which oversees drug regulation, among other things.

Kennedy Jr. has previously voiced criticism for Ozempic, terming it as a means of gladdening the wallets of distant Big Pharma execs. In September, he criticized a New York Times opinion piece on Ozempic saying that the piece failed to acknowledge the causes behind obesity such as “our sickening food system” and sedentary lifestyle.

“According to the writer, obesity seems to be a matter of lack—a lack of bariatric surgeries and a lack of Ozempic courtesy of Novo Nordisk, a Danish multinational whose wealth is bigger than Denmark’s entire economy. As this drug becomes more widely available, the journalist seems to suggest, ‘America’s biggest health problem’ will be under control,” he wrote about the piece on social media platform X.

“Instead of fixing our food system and addressing the obesity crisis at its root, the author focuses on a drug that may palliate the symptom – and gladden the wallets of distant Big Pharma execs.”

“When I’m working in the next administration, I will address our sick food system—and the corrupt government agencies—to help make our country healthy again,” Kennedy Jr. then said while also adding that people should consider kitchen gardens instead of sending money to Denmark.

The MSM cheerleading for Ozempic has begun! New op-ed in the NYT “Opinion | Is Obesity a Disease? It’s Complicated in the Age of Ozempic” does make a valid point: that weight-shaming is cruel and that obesity is not a failure of character (we are not, she rightly and humanely…

— Robert F. Kennedy Jr (@RobertKennedyJr) September 26, 2024

Check out more of Benzinga’s Future Of Mobility coverage by following this link.

Read Next:

  • Jeff Bezos’ Blue Origin Gets License From FAA For New Glenn’s Maiden Launch As It Takes On Elon Musk’s SpaceX Falcon

Photo courtesy: Shutterstock

Previous Post

Debt Limit Concerns: A Potential Investor Opportunity

Next Post

Boeing Faces Talent Drain Amid Space Industry Boom

Next Post

Boeing Faces Talent Drain Amid Space Industry Boom

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent News

Protect Wealth Amid Global Uncertainty: Invest Strategically

June 23, 2025

Stocks Poised for Focus Amid Pre-Market Earnings Buzz

June 23, 2025

Carnival Earnings: Analysts Project Key Growth Trends

June 23, 2025

China Slams US At UN Over Iran Nuclear Strikes: Warns Of ‘Spiraling Escalation’ In Middle East, Demands Immediate Ceasefire

June 23, 2025

Browse by Category

  • Artificial Intelligence
  • Business
  • Crypto
  • Economy
  • Gold
  • In Partnership with Preserve Gold
  • Partnership with InvestorPlace
  • Partnership with The Oxford Club
  • Personal Finance
  • Real Estate
  • Sponsored
  • Stocks
  • Tech
  • Wall Street Word
  • Whale Tracker

Recent News

Protect Wealth Amid Global Uncertainty: Invest Strategically

June 23, 2025

Stocks Poised for Focus Amid Pre-Market Earnings Buzz

June 23, 2025
  • Privacy Policy
  • Terms of Use
  • CCPA Privacy Notice
  • SMS Terms

© 2025 - InvestingPioneers.com.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Wall Street Word
  • Whale Tracker
  • Stocks
  • Gold
  • Crypto
  • Economy

© 2025 - InvestingPioneers.com.